Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
AssigneeBaylor College of Medicine
InventorsAnn Marie Leen, Juan F. Vera
Life of this patent
Estimating the term…
Abstract
Disclosed are compositions and methods related to rendering ineffective Th1 T cells resistant to the inhibitory cytokine milieu present in a cancer microenvironment. Tumor-specific T cells are modified to employ a chimeric receptor that binds inhibitory/suppressive cytokines and converts their intracellular consequences to a Th1 immunostimulatory/activating signal. The T cells employ a chimeric antigen receptor having exodomains for IL10, IL13 and/or IL4 fused with the signal transducing endodomains for IL2 and/or IL7.
Claims6
A method of treating cancer in an individual, comprising the steps of delivering by direct injection into a cancer in the individual a therapeutically effective amount of autologous T cells comprising:
- (1) a chimeric cytokine receptor comprising a cytokine binding exodomain and a signal transducing endodomain, wherein the chimeric cytokine receptor comprises an interleukin-4 (IL-4) receptor exodomain and an IL-7 receptor endodomain, and
- (2) a chimeric antigen receptor that targets an antigen expressed by said cancer;
- wherein the cancer expresses IL-4.
Dependencies are inferred from the claim text.